Business Wire

Scientist.com Announces Launch of Research Marketplace for BIAL

Share

Scientist.com, the biopharma industry’s leading R&D platform, today announced the launch of a private online marketplace for BIAL. The partnership will connect BIAL researchers with over 4,000 pre-signed service providers available on Scientist.com’s digital platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005035/en/

"As a leading Neuroscience R&D pharmaceutical company, we understand the importance of having reliable access to information, efficient processes and the right resources. That is why we are excited to partner with Scientist.com to streamline our R&D efforts and connect with the best scientific research partners and solution providers,” said Joerg Holenz, General Manager of BIAL R&D. “With this partnership, we can better focus on what matters most: delivering innovative solutions to cure diseases."

BIAL is an R&D focused pharmaceutical company that is headquartered in Portugal and has operations in various locations around the world, notably in the most competitive European pharmaceutical markets. The company is committed to discovering, developing and bringing to market innovative medicines. BIAL's main focus is on two therapeutic areas: Parkinson's Disease, which affects more than 10 million people globally, and epilepsy, which impacts over 50 million people worldwide.

"At Scientist.com, we are committed to supporting companies like BIAL that are dedicated to improving the lives of people living with neurological diseases. BIAL's innovative medications are making a real impact on a global scale, and we are proud to partner with them and support their commitment to discovering and developing new treatments in the neurosciences. Together, we can make a difference in the lives of those who need it most,” said Kevin Lustig, PhD, CEO and Founder of Scientist.com.

Scientist.com currently operates award-winning research marketplaces for 24 of the world’s top 30 pharmaceutical companies, over 100 biotech companies and the National Institutes of Health (NIH). The company’s Science as a Service® platform digitizes a company’s entire research operations, enabling researchers to focus more of their time on experimental design and results analysis. Scientist.com helps researchers outsource everything but the genius.

About BIAL

BIAL is an innovation-driven pharmaceutical company aiming to improve people’s lives worldwide. With 98 years of experience, BIAL is strongly committed to therapeutic innovation, consistently investing over 20% of its annual turnover in R&D, being neurosciences its major area of research. Based on its own innovative medicines and with a consistent partnering program, BIAL has extended its presence worldwide. The company has ten affiliates in three different continents – Europe, America and Africa – and its products are present in fifty countries, fulfilling its purpose of making a real difference in the lives of people all over the world.

For more information about BIAL, please visit www.bial.com.

About Scientist.com

Scientist.com's mission is to empower and connect scientists worldwide. The company's digital research platform combines a custom-built, cloud native technology stack with white-glove customer and scientific support to enable scientists to run more innovative experiments in less time and at lower cost. Scientist.com leverages internally developed machine learning models to provide actionable insights that improve operational efficiency and effective research management. Scientist.com connects the world's top pharmaceutical companies, biotechnology companies and the US National Institutes of Health (NIH) to the world's largest network of scientific suppliers.

Join Scientist.com on social media: YouTube, LinkedIn, Twitter, Facebook and Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sean Preci
marketing@scientist.com
+1 858-815-9274

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

More Than Half of Visitors to teamLab Planets in Toyosu, Tokyo Now Come From Overseas. Starting in March, Artworks Featuring Cherry Blossoms That Bloom Across the Space Will Be on View for the Spring Season Only27.1.2023 20:00:00 EET | Press release

Approximately 100,000 people from overseas visited teamLab Planets in Toyosu, Tokyo, between December 9, 2022 and January 9, 2023. (*1) Of the visitors across one month, around 60% , or 1 in 2 visitors, were non-residents visiting Japan (*1), and the number of visitors from overseas has tripled compared to the same month in 2019 (before COVID-19). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230126005440/en/ teamLab, Floating in the Falling Universe of Flowers © teamLab Furthermore, according to a survey conducted by the museum, about 70% of the visitors from overseas knew about the museum before considering their trip to Japan, and there was a trend of the museum being one of the main purposes to visit Tokyo. (*2) *1 From the official website tickets purchaser data (survey period: December 9, 2022 - January 9, 2023) *2 From the visitor survey data (survey period: December 17, 2022 - January 10, 2023) We will continue to p

Global Processing Services Appoints Former Visa Executive Jim McCarthy to Lead Global Sales and Product27.1.2023 13:01:00 EET | Press release

Global Processing Services (“GPS”), a fast-growing next-gen global payments technology platform, today announced the appointment of Jim McCarthy as Executive Vice President – Global Head of Sales and Product, and Kevin Fox as the company’s new Chief Revenue Officer. In this newly created role, Jim will lead GPS’ global commercial and product teams in close collaboration with Kevin on sales acceleration. Jim is a highly accomplished payments veteran with over 30 years of experience, including 18 years at Visa where he held senior roles in sales, risk and authentication, consumer credit, digital products and product innovation. As Visa’s EVP of Innovation and Strategic Partnerships, Jim was responsible for the development of Visa’s product and technology roadmap, innovation efforts, and led business development for strategic partnerships. While at Visa he was responsible for the introduction of 3D Secure and Visa Token Service, which have become industry standards, and also contributed t

Major Landowner Federations to Support AMR Against Nordic Mining ASA (NOM) in the Norwegian Supreme Court27.1.2023 12:59:00 EET | Press release

Key landowner federations declare 3rd party intervention in support of Arctic Mineral Resources’ appeal to the Supreme Court in the case against Nordic Rutile AS (NRU), a wholly owned subsidiary of Nordic Mining ASA (NOM). Arnold Rørholt, lawyer and AMR’s Chairman, welcomes the 3rd party intervention in favour of AMR: “The intervention will ensure that the Supreme Court, as opposed to the courts of lower instance, appreciates the principal nature of the case and the Constitutional issues underpinning it, and interprets the Mineral Act in light of these – to the favour of AMR.” “The Western part of the Engebø garnet and rutile province contains around half of the proven reserves in the Engebø deposit, as well as a majority of inferred resources and will support a highly profitable 50 years plus fully underground mining project without a need for deposits on land or in the sea” continues Rørholt. Arctic Mineral Resources (AMR) and the federations argue that the two mineral categories – o

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.27.1.2023 09:00:00 EET | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended not to grant marketing authorization for investigational palovarotene as a treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP). In the E.U. there are currently only symptomatic treatments for FOP, which do not reduce the formation of extra-skeletal bone in patients with the condition. Ipsen will be requesting a re-examination of the CHMP opinion, based on scientific data available from the existing palovarotene clinical trial program. FOP causes permanent and continuous new bone formation in soft and connective tissues, like muscles, tendons and ligaments, a process known as heterotopic ossification (HO).1 Once formed, it is irreversible.1 The average age of diagnosis is 5 years old2 and ultimately FOP shortens the median life expectancy to 56 years as untimely death is

Green Steel Technology Company Boston Metal Announces $120M Series C Financing Led by ArcelorMittal27.1.2023 08:01:00 EET | Press release

Boston Metal, a company developing technology to fully decarbonize steel production, today announced the $120 million first close of Series C fundraising led by multinational steel company, ArcelorMittal S.A. (NYSE: MT). Microsoft's Climate Innovation Fund and SiteGround Capital also joined as new investors in this round, alongside current investors. ArcelorMittal’s lead investment was made through its XCarb® Innovation Fund. Commenting, Aditya Mittal, CEO, ArcelorMittal, said, “In Boston Metal, we are investing in a team that has made impressive progress over a relatively short period of time, developing a technology that has exciting potential to revolutionize steelmaking. In our extensive discussions with them, we have been impressed by the passion and vision they have to contribute to the decarbonization of steelmaking. They are an exciting and welcome addition to the XCarb® Innovation Fund’s portfolio.” Boston Metal’s patented Molten Oxide Electrolysis (MOE) process is being comme

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom